Sbir phase 1 topic 237: gylcan arrays for biomarker discovery and validation

Ended Definitive Contract Awarded Last action

Contract number
HHSN261200700063C
Awardee
Awarding agency
Obligated
$150,000

Award facts

Contract value 100% obligated
$150,000.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
Not on record
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 2 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
La Jolla, CA 92037, USA
Research
STTR Phase I

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action 1 $0
Original award $150,000

About this award

This is a Small Business Innovation Research (SBIR) Phase 1 contract awarded by the U.S. Department of Health and Human Services (HHS) to Siamab Therapeutics, Inc., a for-profit organization. The contract is for the research and development of glycan arrays for biomarker discovery and validation, with a ceiling value of $150,000 and a completion date of September 29, 2008. The contract was awarded as a Firm Fixed Price Definitive Contract on September 30, 2007 under a Total Small Business set-aside.

Quick answers

Who was awarded contract HHSN261200700063C?

HHSN261200700063C was awarded to Siamab Therapeutics, Inc. by National Cancer Institute (National Institutes of Health) on September 30, 2007.

How much is contract HHSN261200700063C worth?

The government has obligated $150,000 on HHSN261200700063C.

Was contract HHSN261200700063C competed?

The extent of competition for HHSN261200700063C was full and open competition after exclusion of sources. The government received 2 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award